Author + information
- Robert A. Kloner, MD, PhD∗ (, )
- Culley Carson III, MD,
- Adrian Dobs, MD,
- Stephen Kopecky, MD and
- Emile R. Mohler III, MD
- ↵∗Huntington Medical Research Institutes, 10 Pico Street, Pasadena, California 91105
We thank Dr. Čulić for his interest in our review paper on testosterone (1). The focus of our paper was on the role and safety of testosterone replacement therapy in the clinical setting. Due to page limitations, we were unable to cover every aspect regarding experimental preclinical or epidemiology studies dealing with testosterone and the cardiovascular system, nor was that our intent. The studies described by Dr. Čulić certainly are of interest, but at the present time we did not find any well done clinical studies documenting that testosterone replacement therapy was useful for patients with heart failure due to diastolic dysfunction with preserved ejection fraction. Certainly, the experimental and epidemiologic literature referred to by Dr. Čulić suggests that such a clinical trial might be warranted. However, such data are not available at the current time. As we point out in the original paper, there are studies suggesting that testosterone may be useful for patients with heart failure due to reduced ejection fraction, but here there is also a need for larger long-term studies to determine not only the effects of testosterone on symptoms and signs of heart failure and exercise tolerance, but also a need to determine the long-term effects of testosterone replacement therapy on survival in heart failure patients.
Please note: Dr. Kloner is a consultant to Abbvie, Teso-Rx and Lipocine. Dr. Carson is a consultant to Abbvie, Boston Scientific, and ENDO. Dr. Dobs serves on the advisory board to Abbvie. Dr. Kopecky is a consultant to Prime Therapeutics. Dr. Mohler is a consultant to Clarus and Abbvie.
- American College of Cardiology Foundation